Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum

被引:23
作者
Yu, Bo [1 ]
Zhang, Guangping [2 ]
Jin, Lingling [3 ]
Zhang, Bo [3 ]
Yan, Dong [1 ]
Yang, Hong [1 ]
Ye, Zuguang [2 ]
Ma, Tonghui [3 ]
机构
[1] Liaoning Normal Univ, Sch Life Sci, Liaoning Prov Key Lab Biotechnol & Drug Discovery, Dalian, Peoples R China
[2] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China
[3] Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2017年 / 8卷
关键词
PAI-1; inhibitor; toddalolactone; fibrinolysis; pharmacology; PLASMINOGEN-ACTIVATOR INHIBITOR-1; LIVER FIBROSIS; FIBRINOLYSIS; THROMBOSIS; GENE; MICE; TIPLAXTININ; EXPRESSION; LIGANDS; BINDING;
D O I
10.3389/fphar.2017.00489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Traditional Chinese medicine has been used to treat a variety of human diseases for many centuries. Zanthoxylum nitidum var. tomentosum is used as an adjuvant to promote blood circulation and remove stasis. However, the mechanisms of improving circulation and other biological activities of Z. nitidum var. tomentosum are still unclear. Plasminogen activator inhibitor-1 (PAI-1) regulates the plasminogen activation system through inhibition of tissue-type and urokinase-type plasminogen activators (tPA and uPA). PAI-1 has been linked to fibrin deposition that evolves into organ fibrosis and atherosclerosis. In the present study, we showed that ethanol extract prepared from Z. nitidum var. tomentosum exhibited PAI-1 inhibitory activity, and identified toddalolactone as the main active component that inhibited the activity of recombinant human PAI-1 with IC50 value of 37.31 +/- 3.23 mu M, as determined by chromogenic assay, and the effect was further confirmed by clot lysis assay. In vitro study showed that toddalolactone inhibited the binding between PAI-1 and uPA, and therefore prevented the formation of the PAI-1/uPA complex. Intraperitoneal injection of toddalolactone in mice significantly prolonged tail bleeding and reduced arterial thrombus weight in a FeCl3-induced thrombosis model. In addition, the hydroxyproline level in the plasma and the degree of liver fibrosis in mice were decreased after intraperitoneal injection of toddalolactone in CCl4-induced mouse liver fibrosis model. Taken together, PAI-1 inhibition exerted by toddalolactone may represent a novel molecular mechanism by which Z. nitidum var. tomentosum manifests its effect in the treatment of thrombosis and fibrosis.
引用
收藏
页数:11
相关论文
共 45 条
[1]  
[Anonymous], [No title captured]
[2]   Anti-Coagulant Therapy With Dabigatran for Cystic Fibrosis Patients [J].
Bansal, Manvi ;
Ren, Clement L. .
PEDIATRIC PULMONOLOGY, 2016, 51 (08) :E29-E30
[3]   The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity [J].
Bijnens, AP ;
Gils, A ;
Stassen, JM ;
Komissarov, AA ;
Knockaert, I ;
Brouwers, E ;
Shore, JD ;
Declerck, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (48) :44912-44918
[4]   Plasminogen activator inhibitor 1: Physiological and pathophysiological roles [J].
Binder, BR ;
Christ, G ;
Gruber, F ;
Grubic, N ;
Hufnagl, P ;
Krebs, M ;
Mihaly, J ;
Prager, GW .
NEWS IN PHYSIOLOGICAL SCIENCES, 2002, 17 :56-61
[5]   Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study [J].
Bollen, Lize ;
Vande Casteele, Niels ;
Peeters, Miet ;
Bessonov, Kyrylo ;
Van Steen, Kristel ;
Rutgeerts, Paul ;
Ferrante, Marc ;
Hoylaerts, Marc F. ;
Vermeire, Severine ;
Gils, Ann .
INFLAMMATORY BOWEL DISEASES, 2015, 21 (03) :570-578
[6]   Inhibition of plasminogen activator inhibitor-1 activity by two diketopiperazines, XR330 and XR334 produced by Streptomyces sp. [J].
Bryans, J ;
Charlton, P ;
ChicarelliRobinson, I ;
Collins, M ;
Faint, R ;
Latham, C ;
Shaw, I ;
Trew, S .
JOURNAL OF ANTIBIOTICS, 1996, 49 (10) :1014-1021
[7]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE DEFICIENT MICE .1. GENERATION BY HOMOLOGOUS RECOMBINATION AND CHARACTERIZATION [J].
CARMELIET, P ;
KIECKENS, L ;
SCHOONJANS, L ;
REAM, B ;
VANNUFFELEN, A ;
PRENDERGAST, G ;
COLE, M ;
BRONSON, R ;
COLLEN, D ;
MULLIGAN, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2746-2755
[8]  
Charlton PA, 1996, THROMB HAEMOSTASIS, V75, P808
[9]  
Chen Wei-xuan, 2015, Zhong Yao Cai, V38, P2358
[10]   Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy [J].
Crandall, DL ;
Elokdah, H ;
Di, L ;
Hennan, JK ;
Gorlatova, NV ;
Lawrence, DA .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1422-1428